Cargando…

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review

Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Yingmei, Dong, Yi, Yi, Lina, Yang, Guifang, Xiao, Mengxia, Li, Qingqing, Zhao, Chen, Ye, Dafu, Yao, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618617/ https://www.ncbi.nlm.nih.gov/pubmed/37920159 http://dx.doi.org/10.3389/fonc.2023.1241475

Ejemplares similares

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
por: Li, Jing, et al.
Publicado: (2021)

MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
por: Piao, Mei-Na, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
por: Wu, Shugui, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
por: Jin, Caibao, et al.
Publicado: (2020)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
por: Song, Bo, et al.
Publicado: (2023)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma
por: Sun, Jiachun, et al.
Publicado: (2022)

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report
por: Atiq, Mohammad O., et al.
Publicado: (2023)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
por: Li, Qingqing, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review
por: Fang, Ruoxin, et al.
Publicado: (2023)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
por: Zakharia, Yousef, et al.
Publicado: (2022)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
por: Liu, Yanyang, et al.
Publicado: (2021)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
por: Cai, Ruoxue, et al.
Publicado: (2023)

First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature
por: Kong, Feng-Wei, et al.
Publicado: (2020)

Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database
por: Chen, Mingjing, et al.
Publicado: (2021)

Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation
por: Wu, Weishuai, et al.
Publicado: (2023)

Computed Tomography Features and Clinicopathological Characteristics of Gastric Sarcomatoid Carcinoma
por: Liu, Yi-yang, et al.
Publicado: (2020)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
por: Chen, Ling, et al.
Publicado: (2023)

First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma
por: Liang, Long, et al.
Publicado: (2022)

Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review
por: Wang, Jianzheng, et al.
Publicado: (2022)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma
por: Takeda, Kazuya, et al.
Publicado: (2016)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
por: Li, Yu-Feng, et al.
Publicado: (2022)

Individual risk and prognostic value prediction by machine learning for distant metastasis in pulmonary sarcomatoid carcinoma: a large cohort study based on the SEER database and the Chinese population
por: Yi, Xinglin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n6ddd103b1135dsiq1i9c67djl